Cleveland Clinic | Strategic Alliance Partners

February 23, 2023

Pradnya D. Patil, MD, FACP, discusses unmet needs that remain to be addressed with the use of immunotherapy in patients with non–small cell lung cancer.

February 14, 2023

Shared insight on recently updated data in acute myeloid leukemia following the ASH 2022 annual meeting.

February 14, 2023

Experts in hematologic oncology review and analyze updated data in chronic myeloid leukemia from ASH 2022.

February 14, 2023

Following the ASH 2022 Annual Meeting, hematologic oncology experts discuss updated data in acute lymphocytic leukemia.

February 02, 2023

Julie Lang, MD, discusses potential applications for the Parsortix® PC1 system in metastatic breast cancer.

January 27, 2023

Despite American Society of Clinical Oncology guidelines calling for introduction of palliative care early in the course of disease, these services remain underused.

January 25, 2023

Daniel Rotroff, PhD, discusses the investigation of biomarkers that could help identify patients with breast cancer who are at risk for developing chemotherapy-induced peripheral neuropathy.

January 23, 2023

Craig Sauter, MD, discusses the rationale for investigating maintenance pembrolizumab following autologous stem cell transplant in patients with T-cell NHL and explained some of the potential challenges of investigating this regimen in a larger prospective trial in this patient population.

January 05, 2023

Megan Kruse, MD, discusses how socioeconomic disparities and access to health insurance can contribute to poorer overall survival (OS) outcomes in adolescent patients with invasive breast cancer.

January 04, 2023

Craig Sauter, MD, discusses important considerations regarding the use of pembrolizumab after autologous stem cell transplant in T-cell non-Hodgkin lymphoma.

December 19, 2022

Craig Sauter, MD, discusses the investigation of pembrolizumab given after stem cell transplant in T-cell non-Hodgkin lymphoma.

December 19, 2022

Omar Mian, MD, PhD, discusses the ongoing investigation into the synchronous up-front setting of metastatic prostate cancer.

December 12, 2022

Momelotinib elicited durable symptom, transfusion independence, and splenic responses through 48 weeks of treatment in patients with myelofibrosis who have anemia and previously received a JAK inhibitor.

November 23, 2022

Suneel Kamath, MD, discusses the current challenges of treating patients with cholangiocarcinoma, the need for more tolerable therapies in this population, and how the significant ORRs and impressive safety profile seen so far with RLY-4008 in the ReFocus trial are indicative of this agent’s efficacy and durability in FGFR2-rearranged cholangiocarcinoma.

November 14, 2022

Shilpa Gupta, MD, discusses the investigation of enfortumab vedotin with or without additional therapy in cisplatin-ineligible metastatic urothelial carcinoma.

November 07, 2022

Drs Sauter and Hill discuss the use of CAR T-cell therapy in patients with lymphomas, the potential for allogeneic CAR T cells, and ways to expand access and address financial toxicity.

November 04, 2022

Shilpa Gupta, MD, discusses the unmet needs of patients with cisplatin-ineligible metastatic urothelial carcinoma.

November 01, 2022

When assessing monoclonal gammopathy it is important to rule out clinically significant associations requiring treatment.

October 31, 2022

Christopher Wee, MD discusses the current treatment landscape for nonmetastatic castration-resistant prostate cancer, and how the success of new diagnostic tools decreases the need for this classification.

October 24, 2022

Megan Kruse, MD, discusses the evolving treatment landscape in HR-positive, HER2-negative breast cancer, how the approval of fam-trastuzumab deruxtecan-nxki has affected sequencing choices in HER2-positive disease, and the importance of addressing racial disparities in breast cancer care.